18F-Fluorodeoxyglucose positron emission tomography-computed tomography imaging in HIV-infected patients with lymphadenopathy, with or without fever and/or splenomegaly. (June 2018)

• Record Type: Journal Article
• Authors: Jain, L; Mackenzie, S; Bomanji, JB; Shortman, R; Noursadeghi, M; Edwards, SG; Miller, RF
• Is Part Of: International journal of STD & AIDS. Volume 29:Number 7(2018)
• Page Start: 691
• Page End: 694
• Publication Date: 2018-06
• Subjects: Fever -- lymphoma -- infection -- lymph node biopsy -- HIV infection -- pyrexia of undetermined origin -- Kaposi sarcoma -- Castleman disease -- 18F-Fluorodeoxyglucose positron emission tomography-computed tomography imaging; Sexually transmitted diseases -- Periodicals; AIDS (Disease) -- Periodicals; 616.951
• DOI: 10.1177/0956462417745960
• Languages: English
• ISSNs: 0956-4624

Abstract

We audited whether 18 F-Fluorodeoxyglucose positron emission tomography-computed tomography ( 18 FDG PET-CT) imaging could discriminate between different diagnoses in HIV-infected patients presenting with lymphadenopathy, with or without fever and/or splenomegaly. Maximum standardised uptake (SUVmax ) values were similar in lymphoma and mycobacterial and fungal infections and were lower but similar in those with human herpesvirus (HHV) 8-associated disease and HIV-associated reactive lymphadenopathy. Nodal 18 FDG avidity, with SUVmax ≥10, excluded diagnoses of HHV 8-associated disease and miscellaneous conditions, and HIV-associated reactive lymphadenopathy was additionally excluded in those who had undetectable plasma HIV viral loads. This audit suggests 18 FDG PET-CT imaging did not permit discrimination between specific diagnoses but has utility in identifying lymph nodes with increased avidity that could be targeted for biopsy and in ruling out significant pathology.